MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Fechado

SetorSaúde

2.68 -1.47

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.67

Máximo

2.73

Indicadores-chave

By Trading Economics

Rendimento

-5.9M

247K

Vendas

5.1M

62M

Margem de lucro

0.395

Funcionários

181

EBITDA

-6.1M

7.4M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+156.41% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-162M

726M

Abertura anterior

4.15

Fecho anterior

2.68

Sentimento de Notícias

By Acuity

94%

6%

356 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de set. de 2025, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30 de set. de 2025, 23:43 UTC

Ações em Alta

Stocks to Watch: GEO Group, Lithium Americas, Nike

30 de set. de 2025, 23:12 UTC

Ganhos

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30 de set. de 2025, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30 de set. de 2025, 22:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Lifeway Foods, Danone Agree to Stay Litigation

30 de set. de 2025, 21:17 UTC

Ganhos

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30 de set. de 2025, 20:47 UTC

Ganhos

Nike 1Q Sales Rise as Turnaround Progresses

30 de set. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30 de set. de 2025, 23:45 UTC

Conversa de Mercado

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30 de set. de 2025, 23:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30 de set. de 2025, 23:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30 de set. de 2025, 23:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30 de set. de 2025, 23:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30 de set. de 2025, 23:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30 de set. de 2025, 22:54 UTC

Conversa de Mercado

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30 de set. de 2025, 22:38 UTC

Ganhos

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 de set. de 2025, 22:32 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de set. de 2025, 22:32 UTC

Conversa de Mercado

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30 de set. de 2025, 22:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 de set. de 2025, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 de set. de 2025, 21:02 UTC

Ganhos

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 de set. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

30 de set. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

30 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

30 de set. de 2025, 20:28 UTC

Ganhos

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30 de set. de 2025, 20:22 UTC

Ganhos

Nike 1Q North America Revenue $5.02B >NKE

30 de set. de 2025, 20:22 UTC

Ganhos

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30 de set. de 2025, 20:22 UTC

Ganhos

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30 de set. de 2025, 20:22 UTC

Ganhos

Nike 1Q Greater China Revenue $1.51B >NKE

30 de set. de 2025, 20:19 UTC

Ganhos

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Comparação entre Pares

Variação de preço

Akebia Therapeutics Inc Previsão

Preço-alvo

By TipRanks

156.41% parte superior

Previsão para 12 meses

Média 7 USD  156.41%

Máximo 8 USD

Mínimo 6 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Akebia Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.345 / N/ASuporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

356 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat